Skip to main content

Table 4 Subgroup analyses for PGF or PT post-transplantation

From: Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial

Characteristics Low-risk arm (group C), %(95% CI) High-risk arm  
NAC prophylaxis cohort (group A), %(95% CI) Control cohort (group B), %(95% CI) P value
Diagnosis
 AML 12.2(3.6–20.8) 4.8(0–11.4) 18.2(1.4–35.0) 0.088
 ALL 10.4(1.8–19.0) 10.2(0.6–19.8) 27.8(7.0–48.6) 0.106
Donor age
 <45 9.5(2.3–16.7) 5.2(0–12.4) 18.2(1.6–34.8) 0.102
 ≥45 14.2(3.6–24.8) 9.5(0.7–18.3) 27.8(7.0–48.6) 0.083
Donor-recipient relationship
 Parents 9.6(1.4–17.8) 10.2(1.5–18.9) 30.0(9.2–50.8) 0.050
 Others 13.2(4.0–22.4) 3.2(0–9.4) 15.0(0–31.2) 0.128
Pre-HSCT chemo cycles
 <4 18.3(8.3–28.3) 9.7(0.5–18.9) 19.0(1.6–36.4) 0.331
 ≥4 2.2(0–6.6) 5.1(0–12.0) 26.3(5.5–47.1) 0.022
Cycles to achieve CR
<2 vs. ≥2 cycles
 <2 11.5(5.0–18.0) 7.8(1.2–14.4) 22.6(7.4–37.8) 0.048
 ≥2 11.1(0–26.3) 6.3(0–18.7) 22.2(0–51.8) 0.234
Infused CD34+ cells, 106/kg
 <3 13.6(0–22.0) 12.2(2.0–22.4) 31.6(9.8–53.3) 0.084
 ≥3 7.7(0–16.1) 2.6(0–5.3) 14.3(0–29.9) 0.084
  1. Abbreviations: NAC N-acetyl-L-cysteine, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CI confidence interval, HSCT hematopoietic stem cell transplantation, chemo chemotherapy, CR complete remission